Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 54 clinical trials
Clinical Trial of Atezolizumab With Paclitaxel Trastuzumab and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

This is a single arm, Phase IIA clinical trial assessing the safety and efficacy of atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in 50 patients with locally advanced

tumor cells
ejection fraction
measurable disease
her-2 positive breast cancer
pertuzumab
  • 82 views
  • 31 Jan, 2021
  • 1 location
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab

The goal in this Phase 1 dose-escalation trial of the anti-IL-6R monoclonal antibody tocilizumab in combination with trastuzumab and pertuzumab in subjects with metastatic HER2 positive breast

metastasis
erbb2
her2/neu-positive breast cancer
pertuzumab
mammogram
  • 22 views
  • 24 Jan, 2021
  • 3 locations
Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer

This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer

carboplatin
plasma creatinine
serum pregnancy test
rifaximin
platelet count
  • 0 views
  • 25 Jan, 2021
  • 1 location
TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer

This study is to evaluate the efficacy and safety ofTCHP (docetaxel/carboplatin/trastuzumab/Pertuzumab) and EC followed by THP(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab

  • 0 views
  • 23 Jan, 2021
  • 1 location
A Single Arm Phase II Study of ADjuvant Endocrine Therapy Pertuzumab and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive HER2-positive Breast Cancer

This research study is studying a combination of HER2-directed therapies (trastuzumab and pertuzumab) and hormonal therapy as a treatment after surgery for hormone receptor positive breast

  • 0 views
  • 24 Feb, 2021
  • 1 location
S1613 Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer

tumor cells
endocrine therapy
tubal ligation
brain metastasis
measurable disease
  • 419 views
  • 28 Jan, 2021
  • 817 locations
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer

This phase I/II trial studies the side effect and best dose of neratinib and to see how well it works with paclitaxel and with or without pertuzumab and trastuzumab before combination

tumor cells
estrogen receptor
liver metastasis
ejection fraction
carcinoma
  • 12 views
  • 03 Mar, 2021
  • 2 locations
A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)

combination with the dual anti-HER2 blockade consisting of trastuzumab biosimilar ABP 980 and pertuzumab in early breast cancer patients with molecular HER2-enriched intrinsic subtype tested by PAM50.

breast cancer staging
erbb2
progesterone receptor
primary tumor
estrogen
  • 89 views
  • 26 Jan, 2021
  • 15 locations
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab

A phase 2 open-label, randomized, multi-center trial to evaluate the efficacy and safety of neoadjuvant trastuzumab, pertuzumab and weekly paclitaxel (THP) as compared to neoadjuvant trastuzumab

epidermal growth factor
pertuzumab
immunostimulant
neutrophil count
targeted therapy
  • 18 views
  • 27 Jan, 2021
  • 2 locations
The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)- Status in Patients With Metastatic Breast Cancer HER2 + and ER Neg Treated With Trastuzumab + Pertuzumab + Taxane.

This is an exploratory, prospective and multicentric study aiming to highlight by FES-PET imaging that an anti-HER2 treatment by trastuzumab + pertuzumab can reverse the ER status in patients

metastasis
estrogen receptor
taxane
stage iv breast cancer
progesterone receptor
  • 6 views
  • 03 Feb, 2021
  • 7 locations